Infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Acetylcysteine for Adults with Acute Infection or Sepsis and Liver Dysfunction https://clinicaltrials.eu/trial/acetylcysteine-for-adults-with-acute-infection-or-sepsis-and-liver-dysfunction/ Tue, 02 Jun 2026 09:56:41 +0000 https://clinicaltrials.eu/trial/acetylcysteine-for-adults-with-acute-infection-or-sepsis-and-liver-dysfunction/ This clinical trial is studying adults with acute infection or sepsis who also have signs of liver dysfunction, which means the liver is not working properly. The treatment being tested is N-acetylcysteine, also called acetylcysteine, given as an intravenous infusion into a vein. The study is being done to see whether this treatment can improve recovery and reduce time spent in the hospital.

People in the study are assigned by chance to receive either acetylcysteine or sodium chloride. The treatment is given during the hospital stay, and the study then follows the course of recovery over the next days and months. The study looks at how well participants do after treatment, including survival and length of hospital stay, without using complicated procedures in the description.

Sepsis is a serious reaction to infection that can quickly become life-threatening. Liver dysfunction means the liver is injured or not working normally. The purpose of this study is to assess whether acetylcysteine can help adults with severe infection and liver dysfunction recover better.

]]> Testing Personalized Drug Combination Treatment to Reduce Deaths in Patients with Severe Acute Infections https://clinicaltrials.eu/trial/testing-personalized-drug-combination-treatment-to-reduce-deaths-in-patients-with-severe-acute-infections/ Wed, 29 Apr 2026 15:08:52 +0000 https://clinicaltrials.eu/trial/testing-personalized-drug-combination-treatment-to-reduce-deaths-in-patients-with-severe-acute-infections/ This study involves patients with severe acute infection, which is a serious condition where harmful germs such as bacteria or viruses invade the body and cause widespread illness that can affect multiple organs. The study will use four different medications that may be given based on individual patient needs: hydrocortisone (a steroid medication that helps reduce inflammation and supports the body’s stress response, available as tablets or injection), acetylcysteine (a medication given through a vein that helps protect organs from damage), and ferric derisomaltose (an iron supplement given through a vein to treat low iron levels in the blood). The purpose of the study is to determine if a treatment approach tailored to each patient’s specific needs can reduce the number of deaths and shorten the time patients spend in the hospital.

Patients in this study will be adults admitted to the hospital with suspected infection who show signs that their organs are not working properly. They must have been admitted within 72 hours with an infection that doctors expect will require hospital care for more than 24 hours. The study will compare patients who receive individualized treatment based on their specific medical problems against those who receive standard care. The treatments may be given alone or in combination depending on what each patient needs, and the treatment period can last up to 8 days for some medications and 1 day for others.

During the study, doctors will monitor patients closely for any side effects and will track how many days patients are alive and out of the hospital at 14 days and 30 days after joining the study. They will also measure other important outcomes such as survival rates at different time points, whether patients need intensive care, how long they stay in the hospital, their quality of life after six months, and whether they need additional treatments such as breathing support, blood pressure medications, or blood transfusions. The study will also track how long patients need antibiotics and whether their antibiotic treatment needs to be changed or increased.

]]> Title: Study of gentamicin, vancomycin and cefazolin antibiotics to prevent infections in women having breast reconstruction surgery with implants https://clinicaltrials.eu/trial/study-on-the-use-of-gentamicin-vancomycin-and-cefazolin-to-prevent-infections-in-women-undergoing-breast-reconstruction-with-implants/ Wed, 29 Apr 2026 14:59:15 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-gentamicin-vancomycin-and-cefazolin-to-prevent-infections-in-women-undergoing-breast-reconstruction-with-implants/ This study focuses on preventing infections in women who undergo breast reconstruction surgery with implants. The research evaluates the effectiveness of a combination of three antibiotics – gentamicin, vancomycin, and cefazolin – applied directly to the surgical area during breast reconstruction procedures. These medications are mixed with sodium chloride solution, which is commonly known as saline solution.

The main purpose of this research is to determine if using these antibiotics locally during surgery can reduce the risk of infection and prevent complications that might lead to implant removal. The study involves patients who are having breast reconstruction surgery with implants, whether the reconstruction is done immediately after breast removal or at a later time.

During the surgical procedure, some patients will receive the antibiotic solution treatment applied around the implant, while others will receive standard care. The study will monitor patients for six months after their surgery to track any complications or issues that might develop. This research aims to find better ways to protect patients from developing infections after breast reconstruction surgery.

]]> Study of Aztreonam-Avibactam and Metronidazole for Children with Serious Gram-Negative Bacterial Infections https://clinicaltrials.eu/trial/study-of-aztreonam-avibactam-and-metronidazole-for-children-with-serious-gram-negative-bacterial-infections/ Wed, 29 Apr 2026 14:24:59 +0000 https://clinicaltrials.eu/trial/study-of-aztreonam-avibactam-and-metronidazole-for-children-with-serious-gram-negative-bacterial-infections/ The study involves children from 9 months to under 18 years who have serious Gram-negative bacterial infections. These infections can appear as Hospital-acquired pneumonia, Ventilator-associated pneumonia, Complicated intra-abdominal infection, Complicated urinary tract infection, Bloodstream infection, or as Sepsis. The experimental treatment is a combination of Aztreonam-Avibactam given intravenous (through a vein), sometimes together with Metronidazole. Participants receive this new regimen or the best available therapy, which are the standard antibiotics normally used for these serious infections.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.

]]>